Potent antitumor activity of cabozantinib, a c‐MET and VEGFR2 inhibitor, in a colorectal cancer patient‐derived tumor explant model

Publisher： John Wiley & Sons Inc

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.136, Iss.8, 2015-04, pp. : 1967-1975

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Personalized cancer therapy using a patient-derived tumor tissue xenograft model: a translational field worthy of exploring further?

By Jin Ketao   He Kuifeng   Li Guangliang   Teng Lisong  

Personalized Medicine, Vol. 7, Iss. 5, 2010-09 ,pp. : 597-606

Future Medicine

Access to resources Recommend Favorite

Clinical Significance of c-met Oncogene Alterations in Human Colorectal Cancer

By  

Oncology, Vol. 56, Iss. 4, 1999-05 ,pp. : 314-321

Karger

Access to resources Recommend Favorite

C‐Met in invasive breast cancer

By  

CANCER, Vol. 120, Iss. 2, 2014-01 ,pp. : 163-171

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characterization of genetic intratumor heterogeneity in colorectal cancer and matching patient‐derived spheroid cultures

By  

Molecular Oncology, Vol. 12, Iss. 1, 2018-01 ,pp. : 132-147

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases

By                      

International Journal of Molecular Medicine, Vol. 30, Iss. 1, 2012-01 ,pp. : 126-132

Spandidos Publications

Access to resources Recommend Favorite